By Lina carolina 
Basal cell carcinomas (BCCs), the most prevalent form of skin cancer, predominantly affect areas of the skin subjected to chronic sun exposure, such as the face. While often treatable, locally advanced BCCs present a significant challenge, frequently requiring complex surgical interventions that can lead to considerable functional and cosmetic deficits. In a groundbreaking development, a collaborative research team from MedUni Vienna and University Hospital Vienna has unveiled promising results from a clinical trial investigating a novel therapeutic approach. Their findings, published in the esteemed journal Nature Cancer, demonstrate that the active substance Talimogene Laherparepvec (TVEC) not only effectively reduced the size of basal cell carcinomas in all study participants but also, in some cases, led to complete tumor regression, thereby simplifying surgical removal and mitigating the need for extensive reconstructive procedures.
Understanding the Challenge of Advanced Basal Cell Carcinoma
Basal cell carcinoma arises from the basal cells, the deepest layer of the epidermis. Its incidence has been steadily increasing globally, linked overwhelmingly to ultraviolet (UV) radiation exposure from sunlight and artificial sources like tanning beds. While BCCs are typically slow-growing and rarely metastasize, their aggressive local invasion can cause significant tissue destruction, leading to disfigurement and functional impairment, particularly when located on the face, scalp, or ears.
Traditional treatment modalities for BCC include surgical excision, Mohs surgery (a specialized technique for precise tumor removal), curettage and electrodesiccation, cryotherapy, and radiation therapy. However, for tumors that are large, deeply invasive, or located in cosmetically sensitive areas, surgical options can become exceedingly complex. These may necessitate extensive skin grafting or flap reconstruction, carrying risks of infection, scarring, and suboptimal aesthetic outcomes. The need for less invasive, more effective treatments that preserve function and appearance has been a long-standing goal in dermatological oncology.
TVEC: A Novel Oncolytic Virus Therapy
The innovative therapy investigated in this study utilizes Talimogene Laherparepvec (TVEC), a genetically modified oncolytic virus. Oncolytic viruses are engineered to selectively infect and replicate within tumor cells, causing them to lyse (burst) and die, while sparing healthy cells. Crucially, this process also triggers an antitumor immune response, effectively training the patient’s own immune system to recognize and attack cancer cells.
TVEC, specifically, is a modified herpes simplex virus type 1 (HSV-1). It has undergone genetic alterations to enhance its tumor-targeting capabilities and to express the granulocyte-macrophage colony-stimulating factor (GM-CSF), a protein that further stimulates immune activity. Prior to this study, TVEC had received regulatory approval for the treatment of unresectable or metastatic melanoma. This research marks a significant expansion of its potential application to a different type of skin cancer.
The Clinical Trial: Design and Methodology
The clinical trial conducted by the MedUni Vienna and University Hospital Vienna team focused on patients with locally advanced basal cell carcinomas that would have historically required complex reconstructive surgery, such as skin flaps or grafts, due to their size and location. The primary objective was to assess TVEC’s efficacy as a neoadjuvant therapy – meaning it was administered before surgery – to shrink tumors, thereby facilitating less invasive surgical procedures and improving post-operative outcomes.
The study enrolled 18 patients who met these criteria. Each participant received a series of six intralesional injections of TVEC directly into the tumor over a period of 13 weeks. Intralesional administration ensures that the therapeutic agent is delivered precisely to the tumor site, maximizing its local effect. Following the 13-week treatment period, the tumors were surgically removed.
Promising Results: Tumor Reduction and Complete Regression
The outcomes of the study have been remarkably positive. All 18 participants experienced a reduction in the size of their basal cell carcinomas following TVEC treatment. This significant tumor shrinkage proved instrumental in improving the feasibility and outcomes of subsequent surgical interventions.
Crucially, in half of the patients, the tumor was reduced to such an extent that direct wound closure was possible after surgical removal. This bypasses the need for complex flaps or skin grafts, leading to simpler procedures, shorter recovery times, and a reduced risk of complications.
Furthermore, in a notable subset of patients, approximately one-third of the study cohort, the subsequent histological examination of the surgically removed tissue revealed no evidence of living tumor cells. This indicates a complete pathological response, where the therapy effectively eradicated all detectable cancer cells within the tumor bed.
The study also reported that no tumors continued to grow during the TVEC therapy period, underscoring its consistently inhibitory effect on tumor progression. The treatment was also found to be well-tolerated by the participants, with no major adverse events reported, further enhancing its appeal as a viable therapeutic option.
Expert Commentary and Implications
Professor Christoph Hütter, Head of the Skin Tumour Centre at the Department of Dermatology at MedUni Vienna and the principal investigator of the study, expressed optimism about the findings. "This enabled the tumour to be reduced in size in half of the patients to such an extent that surgery with direct wound closure was possible. In a third of the cases, the subsequent histological examination even showed no more living tumour cells. All treated tumours at least became smaller, and no tumour grew further under the therapy. The treatment was well tolerated by the patients," he stated. Professor Hütter emphasized that this novel treatment option for basal cell carcinoma holds the potential to not only simplify surgical procedures but also to significantly reduce the likelihood of disfiguring operations and the imposition of functional limitations on patients.
Dr. Julia Ressler, the first author of the study and also affiliated with the Department of Dermatology, echoed these sentiments. She highlighted the dual benefit of the therapy: improving surgical outcomes and preserving the patient’s quality of life. "The new treatment option for basal cell carcinoma can not only simplify surgery, but also help to avoid disfiguring operations and functional limitations," she added.
Immune System Activation: A Deeper Understanding
Beyond the direct tumor-shrinking effects, the research team conducted extensive analyses to understand the underlying mechanisms of TVEC’s efficacy. In collaboration with St. Anna Children’s Hospital, they performed comprehensive investigations into the immune response within the tumor tissue. These analyses revealed that TVEC therapy significantly strengthens the immune defense in the tumor microenvironment. This enhanced immune surveillance is believed to play a critical role in both eliminating existing tumor cells and preventing recurrence. The oncolytic virus’s ability to induce a robust immune response is a key differentiator from traditional surgical or radiation therapies, offering a potential pathway to more durable remissions.
Future Directions and Broader Impact
The results of this Phase II clinical trial are highly encouraging and strongly suggest that TVEC could represent a promising neoadjuvant treatment strategy for basal cell carcinoma, particularly for patients who would otherwise face extensive surgical interventions. The ability to downstage tumors prior to surgery could fundamentally alter the treatment paradigm for advanced BCCs, leading to improved patient outcomes and a higher quality of life.
The researchers are planning further studies to confirm these benefits in a larger and more diverse patient population. These larger-scale trials will be crucial for solidifying the evidence base, determining optimal dosing and treatment schedules, and comparing TVEC’s efficacy and safety against existing treatment standards.
The potential implications of this research extend beyond BCC. The success of TVEC in this study could pave the way for its investigation in other types of skin cancers or even in non-melanoma skin malignancies that are currently difficult to treat surgically. The concept of using oncolytic viruses to both directly attack cancer cells and harness the power of the immune system is a rapidly evolving field with immense therapeutic potential.
This advancement underscores the importance of continuous innovation in cancer research and highlights the dedication of institutions like MedUni Vienna and University Hospital Vienna in pushing the boundaries of medical science to improve patient care. The publication in Nature Cancer, a journal renowned for its rigorous peer review and high impact, further validates the significance of these findings and their potential to reshape the management of basal cell carcinoma. As research progresses, the prospect of less invasive, more effective treatments for this common form of skin cancer appears closer than ever.
